- Statement of Gene R. Haislip before the Commerce Committee Subcommittee on Oversight and Investigations June 7, 2001
- Address of Gene R. Haislip, Esq. before the Annual Meeting of National Association of State Controlled Substances Authorities in Charleston, South Carolina, Oct. 27, 1998
- An Address by Gene R. Haislip, B.A., LL.B., LL.M. Before the Interpol Conference of Heads of National Drug Services In Antwerp on April 29, 1998
- Address of Gene R. Haislip before the Third Committee of the 47th Session of the United Nations General Assembly, November 3, 1992
An Agency of Diversion Control should be established which would be separated from the DEA, as an effort to split the unique responsibilities of controlling chemicals, from the traditional law-enforcement roles and objectives of the DEA.
The problem of counterfeit drugs has escalated in virtually all countries, and there is no hope of stopping it without a stronger international regulation. As I pointed out in my testimony before Congress, there is no DEA or other police forces focused on this issue.
This is contrary to the specific provisions of Article 10 of the Psychotropic Convention. The government and industry are pretending that such advertising is a right guaranteed by freedom of speech, although it never was considered to be before. This is a fabrication for the purpose of greater commercialization. Virtually every year the amphetamine and Ritalin market grows and has even been extended to infants. Ambien is also one of the drugs that has been heavily marketed through advertising. This practice should be regulated and confined to medical journals as it always was.